AAML1031Induction de type (Cytarabine + Daunorubicin + Etoposide, pédiatrique AML 1L)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Composantes	`DRUG-CYTARABINE` `DRUG-DAUNORUBICIN` `DRUG-ETOPOSIDE`

ID	`REG-AAML1031-PEDIATRIC`
Type	Protocole thérapeutique
État	reviewed 2026-04-27 \| pending_clinical_signoff
Maladies	Aucune déclaration
Sources	`SRC-ESMO-AML-2020` `SRC-NCCN-AML-2025`

Notes

AAML1031 (Aplenc 2020/Pollard 2021, JCO; Children's Oncology Group): pediatric AML 1L backbone for non-DS, non-APL AML age <30. Induction I = ADE 10+3+5 (cytarabine + daunorubicin + etoposide). Risk stratification at end-induction by cytogenetics, MRD, FLT3-ITD AR, WT1-mutant, CEBPA, NPM1. Low-risk: 5 cycles chemotherapy. High- risk: alloHCT in CR1 (matched related/unrelated). Bortezomib add-on did NOT improve outcome (AAML1031 randomization). Ongoing successor: AAML1831 (with venetoclax + GO + selinexor depending on biology). Pediatric AML in Ukraine — typically managed at Окхматдит / regional pediatric oncology centres per NMRC consensus protocol (NMRC Pediatric AML 2022, locally adapted from AAML1031 + Berlin-Frankfurt-Münster AML-BFM 2012/2019). PJP, HSV, antifungal, TLS prophylaxis are non-negotiable. Long-term follow-up: cardiology (anthracycline), endocrinology (GH, gonadal), 2nd malignancy surveillance.

Utilisé par

Indication

IND-AML-PEDIATRIC-AAML1031 - IND-AML-PEDIATRIC-AAML1031